文献速递心律失常

房颤消融术前停用非维生素K拮抗剂口服抗凝药时机的随机研究

When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
PubMed 文献 · Eur Heart J · 2019-01-01

这项前瞻性多中心随机试验将326例房颤消融患者按1:1:1分为不间断用药组、手术日单次跳过组和跳过24小时组,发现三组主要出血及血栓栓塞并发症无显著差异,术中肝素需求在跳过24小时组更高。

要点

  • 不间断NOAC与单次或双次跳过方案在房颤消融围术期安全有效。
  • 跳过24小时组术中肝素需求量更高,但活化凝血时间无差异。
  • 不同NOAC类型间主要出血和血红蛋白下降无显著差异。

核心结论

  • 房颤消融患者采用不间断NOAC、手术日单次跳过或跳过24小时方案,疗效与安全性相当,且不受NOAC类型影响。

研究设计与样本

  • 前瞻性、开放标签、随机多中心试验,纳入326例(75%男性,58±11岁)拟行房颤导管消融患者,按1:1:1随机分配至不间断组、手术日单次跳过组和跳过24小时组,在三个三级医院进行。

主要发现

  • 跳过24小时组术中肝素需求量高于其他组(P < 0.001),平均活化凝血时间组间相当(P = 0.139)。
  • 消融术后1个月内主要出血发生率及术后血红蛋白下降水平在各治疗组和不同NOAC间无显著差异(P > 0.05)。
  • 三组均无致命事件或血栓栓塞并发症。

关键数值与推荐

  • 主要终点为消融术后1个月内出血事件发生率。
  • 次要终点包括血栓栓塞及其他手术相关并发症。
  • 持续性房颤患者分配至跳过24小时组时采用低分子肝素桥接。
  • 达比加群、利伐沙班和阿哌沙班在随机化后按顺序分配。

临床怎么用

  • 房颤消融围术期可考虑不间断NOAC或手术日单次跳过策略,无需常规跳过24小时。
  • 选择跳过24小时方案时需注意术中肝素需求量可能增加。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量有限,仅纳入三种NOAC。
  • 持续性房颤患者跳过24小时组采用低分子肝素桥接可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Although a recent expert consensus statement has recommended periprocedural uninterrupted (UI) non-vitamin K antagonist oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) as a Class I indication, there have been no clear randomized trials. We investigated the safety and efficacy of UI, procedure day single-dose skipped (SDS), and 24-hour skipped (24S) NOACs in patients undergoing AF ablation. METHODS AND RESULTS: In this prospective, open-label, randomized multicentre trial, 326 patients (75% male, 58 ± 11 years old) scheduled for AF catheter ablation were randomly assigned in a 1:1:1 ratio to UI, SDS, and 24S at three tertiary hospitals. Bridging with low molecular weight heparin was carried out in the patients with persistent AF who were assigned to the 24S group. Dabigatran, rivaroxaban, and apixaban were assigned in order after randomization. The primary endpoint was the incidence of bleeding events within 1 month after ablation. The secondary endpoints included thrombo-embolic and other procedure-related complications. The intra-procedural heparin requirement was higher in the 24S group than others (P < 0.001), and the mean activated clotting time was comparable among the groups (P = 0.139). The incidence of major bleeding up to 1 month after ablation and a post-procedural reduction in the haemoglobin levels did not significantly differ among the treatment groups and different NOACs (P > 0.05). There were no fatal events or thrombo-embolic complications in all the three groups. CONCLUSION: In patients undergoing AF ablation, UI NOACs and SDS or double dose skipped NOACs had a comparable efficacy and safety, regardless of the type of NOAC.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Yu HT, Shim J, Park J, et al. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. Eur Heart J. 2019. PMID: 30590600. doi:10.1093/eurheartj/ehy870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。